Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. Taniguchi H, et al. Among authors: mukae h. Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0. Nat Commun. 2019. PMID: 30651547 Free PMC article.
Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin.
Ishimoto H, Mukae H, Sakamoto N, Amenomori M, Kitazaki T, Imamura Y, Fujita H, Ishii H, Nakayama S, Yanagihara K, Kohno S. Ishimoto H, et al. Among authors: mukae h. J Antimicrob Chemother. 2009 Jan;63(1):109-14. doi: 10.1093/jac/dkn427. Epub 2008 Oct 18. J Antimicrob Chemother. 2009. PMID: 18931390
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: mukae h. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S. Taniguchi H, et al. Among authors: mukae h. Cancer Sci. 2017 Jan;108(1):53-60. doi: 10.1111/cas.13111. Epub 2016 Dec 30. Cancer Sci. 2017. PMID: 27783866 Free PMC article.
Primary Mediastinal Large B-cell Lymphoma Exhibiting Endobronchial Involvement.
Shimada M, Fukuda M, Horio K, Suyama T, Kitazaki T, Hashiguchi K, Fukuda M, Shigematsu K, Nakamura Y, Honda T, Ashizawa K, Mukae H. Shimada M, et al. Among authors: mukae h. Intern Med. 2016;55(21):3147-3150. doi: 10.2169/internalmedicine.55.7117. Epub 2016 Nov 1. Intern Med. 2016. PMID: 27803409 Free PMC article.
Pulmonary Artery Sarcoma Overexpressing Platelet-derived Growth Factor Receptor α.
Takemoto S, Soda H, Iwasaki K, Kitazaki T, Sumiyoshi M, Harada T, Dotsu Y, Ogawara D, Fukahori S, Fukuda Y, Mukae H. Takemoto S, et al. Among authors: mukae h. Intern Med. 2017;56(7):823-826. doi: 10.2169/internalmedicine.56.7731. Epub 2017 Apr 1. Intern Med. 2017. PMID: 28381750 Free PMC article.
726 results